Trials / Completed
CompletedNCT05294536
A Pharmacokinetic Study Comparing the Liraglutide Injection (RD12014) and Victoza® in Healthy Chinese Subjects
A Randomized, Open-label, Two-period, and Double-cross Comparative Study on the Pharmacokinetics of Liraglutide Injection (RD12014) and Victoza® in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Sunshine Lake Pharma Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the pharmacokinetics similarity between the liraglutide injection (RD12014) produced by Sunshine Lake Pharma Co., Ltd. and liraglutide injection (Victoza®) produced by Novo Nordisk Pharmaceutical Co., Ltd for single dose in healthy male subjects, as well as to evaluate the similarity of the safety and immunogenicity between RD12014 and Victoza ® in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Liraglutide injection,RD12014 | single dose, s.c. injection |
| DRUG | Liraglutide injection,Victoza | single dose, s.c. injection |
Timeline
- Start date
- 2020-06-22
- Primary completion
- 2020-07-20
- Completion
- 2020-11-27
- First posted
- 2022-03-24
- Last updated
- 2022-03-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05294536. Inclusion in this directory is not an endorsement.